RCS - EKF Diagnostics Hldg - Launch of EKF Link

EKF Diagnostics HoldingsAnnouncement

09/06/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220609:nRSI2279Oa&default-theme=true

RNS Number : 2279O  EKF Diagnostics Holdings PLC  09 June 2022

RNS Reach

EKF Diagnostics Holdings plc

("EKF", the "Company" or the "Group")

 

Launch of EKF Link

 

Digital connectivity solution driven by client demand

Enabling hospitals, labs and GPs to manage and evaluate patient data easily
and securely

 

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics
business, announces the launch of EKF Link, a digital connectivity
solution for the secure management of point-of-care ("POC") analysers and
associated data on one centralised platform. The EKF Link middleware links to
EKF's own product portfolio and can also provide connectivity to selected
third-party POC analysers, to enable real-time remote management of data, such
as patient test results, quality control ("QC") /calibration results, operator
management and analyser configuration.

 

EKF Link is a downloadable software package that allows POC analysers to
connect to a hospital or laboratory's IT system, enabling data transfer from
these remote analysers for subsequent processing, thereby enhancing their
capabilities. This provides hospitals, laboratories and clinicians with the
connectivity and functionality to manage and evaluate their patient and
operator data, easily and securely. It also allows the remote operators to
capture patient information, perform a QC test, lock-out unauthorised users
and transfer information directly into the laboratory information management
system.

 

EKF's portfolio of POC diagnostic devices includes its range of Hematology
analysers: Hemo Control and DiaSpect Tm hemoglobin, as well as its Diabetes
range of analysers: Quo-Lab and Quo-Test HbA1c. All of these can now be
digitally connected from anywhere and securely accessed remotely at any time
using EKF Link, compared to current methods whereby data generated from POC
analysers are either kept as written records, printed out, or in some cases
connected via Bluetooth or data cable.

 

The development and launch of EKF Link has been driven by customer demand and
designed in partnership with hospital POC managers to ensure the software
meets their specific needs. EKF Link provides the Company with improved
competitive positioning for future POC contract tenders and new accounts, and
increases the attractiveness of the EKF product portfolio to existing
customers against currently available technologies.

 

For more information visit: https://www.ekfdiagnostics.com/ekf-link.html
(https://urldefense.proofpoint.com/v2/url?u=https-3A__www.ekfdiagnostics.com_ekf-2Dlink.html&d=DwMFAg&c=euGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM&r=fSst1AtlXyuqcs3cHJXcCRilbI1Qm1WfjNYkVgQfiLE&m=Vk8Ngs_JvA02Agu8ps87XLgcOHOUlZRmuB6v45i7j_w&s=sfz4cIOFxxP1Y1kiv-Ih_qDFFAuEEqJ93Gwn0lV62p0&e=)

 

Mike Salter, CEO, of EKF Diagnostics said: "As part of our strategy to enhance
our POC analyser portfolio and technology offering, we are pleased to announce
that we have successfully launched EKF Link enabling practitioners to analyse
their patients' results remotely, easily and securely. EKF Link provides our
POC diagnostic devices with a connectivity advantage which positions us well
for tenders and new accounts. This is particularly true in Europe and North
America, where a connectivity solution is commonly a part of the
specification. EKF Link has the added benefit that it can be installed
wherever it is needed, on a PC or a central server, allowing hospitals and
laboratories, technicians and clinicians to access results from various
settings, reducing workload whilst increasing the security of handling patient
data.

 

"This new product launch shows our responsiveness to our customer base and
increasing demand for data management capabilities. It extends the utility of
our installed instrument base and provides EKF with a key advantage for
further new business opportunities."

 

 EKF Diagnostics Holdings plc               www.ekfdiagnostics.com (http://www.ekfdiagnostics.com)
 Mike Salter, CEO                            Tel: +44 (0)29 2071 0570
 Marc Davies, CFO

 Singer Capital Markets (Nominated Adviser & Joint Broker)                           Tel: +44 (0)20 7496 3000
 Aubrey Powell / George Tzimas

 Investec Bank plc (Joint Broker)           Tel: +44 (0)20 7597 4000
 Gary Clarence / Daniel Adams / Ben Farrow

 Walbrook PR Limited                        Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com (mailto:ekf@walbrookpr.com)
 Paul McManus / Lianne Applegarth           Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303

 

 

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com
(http://www.ekfdiagnostics.com) )

EKF is a leading global diagnostics business with custom manufacturing
facilities across sites in the US, UK and Europe for a variety of life science
products. EKF is focussed on the following areas:

 

 Point-of-Care             Providing a portfolio of Point-of-Care analysers and consumables, particularly
                           for use in the area of Hematology and Diabetes, for use in hospital and
                           research laboratories, doctor's offices, blood banks and for in-field anaemia
                           screening programmes. EKF has an estimated 80,000 hemoglobin, hematocrit,
                           HbA1c, glucose and lactate analysers in regular use across more than 100
                           countries.

 Central Laboratory        Clinical chemistry, Small lab analysers, Centrifuges

                           Beta-Hydroxybutyrate (β-HB) LiquiColor, Glycates Albumin, Glycated Serum
                           Protein, Nitro-tab, Procalcitonin

 Life Sciences             Enzyme fermentation, Custom products and Bulk fermentation

 Contract Manufacturing    Bulk formulation, Sample collection kits, Private labelling, Molecular and
                           forensic kits

 Laboratory Services       In September 2021, EKF completed the acquisition of Advanced Diagnostic
                           Laboratory LLC ("ADL Health"), a Texas based testing laboratory certified
                           under the Clinical Laboratory Improvement Amendments ("CLIA") for high
                           complexity testing. The laboratory provides testing for a variety of clinical,
                           forensic and microbiological sample types using a range of analytical
                           techniques. This acquisition positions EKF as a leading 'one stop' provider of
                           diagnostic products and services from sample collection to results.

 

EKF's growth strategy to 2024 and beyond can be summarised as:

 •    continuing innovation in products and services in Point-of-Care, Central
      Laboratory and Life Sciences leveraging new and existing routes to market and
      relationships;
 •    investment in expanded production and kitting capabilities to offer a suite of
      diagnostic Contract Manufacturing solutions to third party businesses;
 •    expansion of CLIA Laboratories Testing offering, building on the acquired
      capabilities in ADL Health; and
 •    identify complementary earnings-enhancing acquisitions with key strategic
      value.

 

EKF will also continue to generate enhanced shareholder value through:

 •    a progressive dividend policy; and
 •    its agreement with Mount Sinai Innovation Partners ("MSIP"), which allows us
      advanced access to innovative commercial opportunities and where we can build
      on the ongoing successes of Renalytix plc, Verici Dx plc and Trellus Health
      plc.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAUPUAUQUPPGMR